Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
Yet another combination to consider after CDK4/6i + ET in HR+ MBC!
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Author(s): Francois-Clement Bidard, MD1,2; Virginia G. Kaklamani, MD3; Patrick Neven, MD4; Guillermo Streich, MD5; Alberto J. Montero, MD6; Frédéric Forget, MD7; Marie-Ange Mouret-Reynier, MD8; Joo Hyuk Sohn, MD9; Donatienne Taylor, MD10; Kathleen K. Harnden, MD11; Hung Khong, MD12; Judit Kocsis, MD13; Florence Dalenc, MD14; Patrick M. Dillon, MD15; Sunil Babu, MD16; Simon Waters, MD17; Ines Deleu, MD18; José A. García Sáenz, MD19; Emilio Bria, MD20; Marina Cazzaniga, MD21; Janice Lu, MD22; Philippe Aftimos, MD23; Javier Cortés, MD24,25,26,27; Shubin Liu, MS28; Giulia Tonini, PhD29; Dirk Laurent, MD30; Nassir Habboubi, MD31; Maureen G. Conlan, MD32; and Aditya Bardia, MD33
Source: 10.1200/JCO.22.00338 Journal of Clinical Oncology 40, no. 28 (October 01, 2022) 3246-3256
Dr. Maen Hussein's Thoughts
Coming soon to a pharmacy near you?
ABSTRACT
PURPOSE
Patients with pretreated estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis. Elacestrant is a novel, oral selective ER degrader that demonstrated activity in early studies.
METHODS
This randomized, open-label, phase III trial enrolled patients with ER-positive/HER2-negative advanced breast cancer who had one-two lines of endocrine therapy, required pretreatment with a cyclindependent kinase 4/6 inhibitor, and # 1 chemotherapy. Patients were randomly assigned to elacestrant 400 mg orally once daily or standard-of-care (SOC) endocrine monotherapy. Primary end points were progression-free survival (PFS) by blinded independent central review in all patients and patients with detectable ESR1 mutations.
RESULTS
Patients were randomly assigned to elacestrant (n 5 239) or SOC (n 5 238). ESR1 mutation was detected in 47.8% of patients, and 43.4% received two prior endocrine therapies. PFS was prolonged in all patients (hazard ratio 5 0.70; 95% CI, 0.55 to 0.88; P 5 .002) and patients with ESR1 mutation (hazard ratio 5 0.55; 95% CI, 0.39 to 0.77; P 5 .0005). Treatment-related grade 3/4 adverse events occurred in 7.2% receiving elacestrant and 3.1% receiving SOC. Treatment-related adverse events leading to treatment discontinuations were 3.4% in the elacestrant arm versus 0.9% in SOC. Nausea of any grade occurred in 35.0% receiving elacestrant and 18.8% receiving SOC (grade 3/4, 2.5% and 0.9%, respectively).
CONCLUSION
Elacestrant is the first oral selective ER degrader demonstrating a significant PFS improvement versus SOC both in the overall population and in patients with ESR1 mutations with manageable safety in a phase III trial for patients with ER-positive/HER2-negative advanced breast cancer.
Author Affiliations
1Institut Curie, Paris and Saint Cloud, France; 2Versailles Saint Quentin/Paris-Saclay University, Saint Cloud, France; 3University of Texas Health Sciences Center, San Antonio, TX; 4Universitaire Ziekenhuizen (UZ)—Leuven Cancer Institute, Leuven, Belgium; 5Centro Médico Austral, Buenos Aires, Argentina; 6University Hospitals Seidman Cancer Center-Case Western Reserve University, Cleveland, OH; 7Centre Hospitalier de l’Ardenne—Site de Libramont, Libramont-Chevigny, Belgium; 8Centre Jean Perrin, Clermont-Ferrand, France; 9Yonsei Cancer Center, Yonsei University Health System-Medical Oncology, Seoul, Republic of Korea; 10Université catholique de Louvain, CHU UCL Namur—Site Sainte-Elisabeth, Namur, Belgium; 11Inova Schar Cancer Institute, Fairfax, Virginia; 12Moffit Cancer Center & Research Institute, Tampa, FL; 13Bács-Kiskun Megyei Kórház, Kecskemét, Hungary; 14Institut Claudius Regaud, IUCT-Oncopole, Toulouse, France; 15University of Virginia Cancer Center, Charlottesville, VA; 16Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN; 17Velindre Cancer Centre, Cardiff, United Kingdom; 18AZ Nikolaas, Sint-Niklaas, Belgium; 19Instituto de Investigación Sanitaria Hospital Clinico San Carlos (IdISSC), Madrid, Spain; 20Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; 21Ospedale San Gerardo-ASST Monza, Monza, Italy; 22University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA; 23Institut Jules Bordet – Université Libre de Bruxelles, Brussels, Belgium; 24International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain; 25Scientific Department, Medica Scientia Innovation Research, Valencia, Spain; 26Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; 27Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain; 28Cytel, Waltham, MA; 29Menarini Group, Florence, Italy; 30Berlin Chemie AG/Menarini Group, Berlin, Germany; 31Stemline Therapeutics/Menarini Group, New York, NY; 32Radius Health, Inc, Boston, MA; 33Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MARelated Articles
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial
The INSEMA trial showed that for early stage, T1-T2 clinically node negative breast cancer, sentinel lymph node biopsies should not be mandatory, and best clinical judgement can be used.
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Imlunestrant (novel oral SERD) was active in patients with an ESR1 mutations, but otherwise did not offer a benefit in this population of women with ER+ HER2-neg MBC. Overall survival (OS) data is pending with further follow up.
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
Another trial with neoadjuvant immunotherapy showing improved results over chemotherapy alone. (12% higher PCR 48% vs 36%).
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
Dato-DXd is now approved in HR+, HER2-neg, metastatic breast cancer after prior therapy with endocrine-based therapy and chemotherapy. There was an impressive reduction in the risk of death or progression with an HR of 0.63. Watch out for ocular and pulmonary toxicity. HER2-ultra low testing will be burdensome but must be done for drug approval.
